1216-Microbiota-Immunity Axis in Cancer Checkpoint Blockade
The research explores the critical link between the gut microbiota and the success of immune checkpoint blockade (ICB) in cancer treatment. It highlights how the presence of specific beneficial microbes and their metabolic byproducts, such as short-chain fatty acids, can enhance a patient's immune response against tumors. Conversely, factors like antibiotic use or a low-fiber diet can lead to microbial imbalances that undermine therapeutic efficacy and survival rates. The text also examines how the microbiome influences the development of immune-related adverse effects, such as colitis, which…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.